The procoagulant activity of platelets induced by collagen, membrane, and provide evidence that dense granules may be a major source of ADP which can contribute to calcium thrombin, and collagen plus thrombin, measured as their influx in stimulated platelets. Parallel alterations, including capacity to promote the conversion of prothrombin to both increases and decreases, in the [Ca 2" ] i and prothrombithrombin in the presence of factors Va and Xa, was studied nase responses were also observed in thrombasthenia, dein patients with a, ad, and d storage pool deficiency (SPD), pending on the agonist and stirring conditions. Both rethrombasthenia, and in two new patients with isolated desponses were increased in collagen-stimulated, unstirred fects in platelet coagulant activity, and compared with that platelets, whereas an inability to maintain increased [Ca 2" ] i in Scott syndrome. The most significant abnormality in the levels, associated with decreased prothrombinase activity new patients, whose defect may differ from that in Scott in all but one atypical patient, was seen in stirred collagen syndrome, is an impairment in collagen plus thrombin-inplus thrombin-activated platelets. Although the parallel alduced prothrombinase activity in the absence of added facterations in these responses in thrombasthenia, as in SPD, tor Va. In one of these patients this may be caused by an further show the close association between the generation abnormality in platelet a-granule factor V distinct from that of prothrombinase activity and the maintenance of indescribed for factor V Quebec, ad-SPD, or a-SPD (gray platecreased intracellular Ca 2" levels, the specific role that GPIIblet syndrome). Prothrombinase activity in response to all IIIa may play in both these events remains unresolved. Our agonists was impaired in d-SPD and was associated with an findings of both enhancement and inhibition of these activainability of these platelets to maintain elevated intracellular tion-related events in thrombasthenic platelets may be recalcium levels. Both the rapid decline in agonist-induced lated to previous conflicting reports on the promotion or [Ca 2" ] i levels and the impaired prothrombinase activation in inhibition of fibrin formation by GPIIb-IIIa, and could be reled-SPD platelets were corrected by the addition of adenosine vant to the use of specific inhibitors of GPIIb-IIIa as antidiphosphate (ADP) after stimulation. These findings suggest thrombotic agents. In addition, the study provides further that secreted ADP may play an important role in the generasupport for the concept that the development of agents that tion of prothrombinase activity by contributing to the maincould induce a Scott syndrome defect in normal platelets tenance of a critical [Ca 2" ] i level necessary to maintain may provide a new approach to antithrombotic therapy. aminophospholipids on the outer surface of the platelet ᭧ 1997 by The American Society of Hematology.
T logic agonists such as collagen and thrombin, and their mixture, 6 ,8,11-14 presumably due to their ability to elevate intracel-HE FORMATION of platelet-fibrin thrombi at sites of vascular injury is the principal mechanism involved in both the arrest of bleeding and the formation of clinically lular calcium ([Ca 2/ ] i ). 15, 16 This phospholipid ''flip-flop'' results in the exposure of phosphatidylserine on the outer important occlusive intravascular thrombi. The mechanisms by which platelets adhere to subendothelium and interact layer of the membrane, producing a procoagulant surface 6, 8, 11, 14 that, in the presence of the coagulation factors with platelet agonists such as collagen, thrombin, and adenosine diphosphate (ADP) to promote the formation of platelet involved in tenase and prothrombinase reactions, can increase the rate of thrombin formation by more than 1 millionaggregates at sites of injury have been reviewed. 1,2 Central to the process of platelet aggregation is the formation of fold. 11, 17 The mechanism by which an increase in [Ca -dependent scrambling mechanism that increases the rate of both inward and outfinal common pathway by which all agonists act to initiate platelet aggregation.
WEISS AND LAGES 1600
(RBCs) may involve a protein (''scramblase''), appears to
MATERIALS AND METHODS
be reversible and dependent on a critical [Ca 2/ ] i level. 21, 23, 24 Reagents An abnormality in the translocation of phosphatidylserine to Purified human prothrombin, factor Va, factor Xa, and a-thrombin the platelet surface, 25 associated with impaired prothrombiwere obtained from Haematologic Technologies (Essex Junction, nase 25, 26 and tenase 25 activity, has been described in a patient VT) . International standard human a-thrombin (89/588) was obwith an isolated platelet coagulant defect and a moderately tained from the National Institute for Biological Standards and Consevere bleeding disorder (Scott syndrome). 27, 28 Another patrol (Hertfordshire, UK). Spectrozyme TH was obtained from Ameritient who may have the same type of defect has also been can Diagnostic (Greenwich, CT). Factor V-deficient human plasma described recently. 29 was obtained from Baxter Diagnostics, Inc (Deerfield, IL). Fura-2/
The relationship between the mechanisms involved in the AM came from Molecular Probes (Eugene, OR). 'Horm' collagen was from Nycomed (Munich, Germany) and was diluted into 0.15 transformation of GPIIb-IIIa to its high-affinity ligand-bindmol/L saline just before use, and bovine thrombin, from Parke-Davis ing state and those responsible for the development of the (Morris Plains, NJ) was stored in frozen aliquots of 100 U/mL in platelet coagulant activity (PCA) is presently unclear. Early 0.15 mol/L saline. ADP was from Sigma Chemical (St Louis, MO) studies on patients with thrombasthenia [30] [31] [32] [33] [34] [35] who are deficient and was diluted in Ca-free Tyrode's buffer before use.
in GPIIb-IIIa 36 reported abnormalities in PCA, designated as platelet factor 3 (PF3). These studies used a method in which
Collection of Blood and Preparation of Platelet-Rich PCA was induced by incubating platelet-rich plasma with Plasma (PRP) kaolin and assessing the capacity of the activated platelets Blood was taken into ACD (NIH formula A, 1 vol anticoagulant:
to shorten the recalcification or Russell's viper venom time 6 vol blood) for studies of platelet prothrombinase activity, intracelof platelet-poor plasma. Impaired activation of the contact lular Ca 2/ mobilization in fura-2-loaded platelets, and platelet factor system was also reported. 35 More recent studies have yielded V coagulant activity. Blood was collected into 1/10 vol of 1% EDTA conflicting results. The activated whole-blood clotting time for measurement of platelet vWF antigen (vWF:Ag), and into 1/10 was found to be prolonged in patients undergoing coronary vol 3.2% sodium citrate for assay of platelet factor 3 availability.
angioplasty who received a monoclonal antibody (MoAb)
PRP was prepared by centrifugation of whole blood for 3 minutes to GPIIb-IIIa. 37 However, Bevers et al 38 reported normal at 1,500g at room temperature.
prothrombinase activity in four patients with several types of thrombasthenia. Other studies reported that the absence 39 Platelet Factor 3 Availability (PF3a) or blockade 40 of GPIIb-IIIa actually promoted fibrin forma-A previously described method was used to measure kaolin-intion on subendothelium 39 and collagen, 40 and in the early, duced PF-3a. 27, 31 In this test, 0.4 mL of PRP, adjusted with autolobut not the later, stages of hemostasis as measured in bleedgous platelet-poor plasma (PPP) to a platelet count of 300,000/mL, ing time wounds. 41 A role for GPIIb-IIIa in promoting vesicwas incubated with 0.2 mL of 8% kaolin at 37ЊC for 6 minutes, ulation of the platelet membrane, which has been linked in after which time a 0.05-mL aliquot was transferred to a test tube containing 0.3 mL of normal substrate PPP that had been activated some studies 13 to the development of prothrombinase activwith 0.15 mL of 2% kaolin during the preceding 4 minutes. The ity, has also been proposed, 42 but contrary evidence has been clotting time was determined immediately by the addition of 0.4 mL reported in other studies. reported impaired PF3 availability (PF3a) in patients with secretion defects, 31 some of whom had storage pool defiPlatelet Factor V Coagulant Activity ciency (SPD), 44 a platelet disorder characterized by reduced Platelet factor V coagulant activity was measured in Triton Xcontents of substances stored in dense granules (d-SPD), 100 lysates of gel-filtered platelets (GFP) prepared by mixing 400 dense granules and a-granules (ad-SPD), or a-granules mL of GFP with 11.5 mL of 100 mmol/L Ca(NO 3 ) 2 and 50 mL of (a-SPD, gray platelet syndrome). 45, 46 The impaired PF3a in 1.8% Triton X-100 (Sigma Chemical). Factor V activity in dilutions some of these patients was corrected by the addition of of these lysates was assessed with Thromboplastin
• C Plus (Baxter ADP. 31 However, Bevers et al 38 reported normal platelet proDiagnostics, Inc) by a one-stage clotting assay using factor Vthrombinase activity in three patients with d-SPD and three deficient human substrate plasma (Baxter). The average value in with a-SPD. These latter findings suggested that platelet normal subjects (n Å 15) was 68 U/10 11 platelets ({2 SD Å 31 to granules, or their secretion, were not required for the devel-105). The assay used measures the coagulant platelet factor V that opment of prothrombinase activity, a conclusion that gained is stored as a partially proteolyzed, active cofactor, 47 as well as any support from later studies on normal platelets. 13 factor V that is activated to Va by thrombin formed during the assay.
To examine these questions further, we have performed Platelet vWF:Ag studies on agonist-induced platelet prothrombinase activity in 5 patients with thrombasthenia and 20 patients with variPlatelet vWF:Ag in washed platelets was assayed by electroimmuous types of SPD (a, ad, and d). The results obtained have noassay, as described previously. 48 The average value in normal been compared with our previously described patient with subjects (n Å 31) was 43 U/10 11 platelets ({2 SD Å 20 to 66).
Scott syndrome in whom a defect in prothrombinase activity Platelet b-Thromboglobulin (b-TG) is not associated with any aggregation, secretion, or granule defect. In addition, we describe two new patients with this b-TG was assayed in Triton X-100 lysates of GFP using an Astype of defect. In addition to measuring prothrombinase ac- ing agonist-induced platelet activation were also performed. , 0.1% glucose, and 0.2% bovine and gel-filtered into Ca-free Tyrode's elution buffer as described albumin as described previously. 49 Prothrombinase activity in GFP previously. 51 The increases in [Ca 2/ ] i induced by collagen, thrombin, was assayed by a modification of the method of Weidmer et al. 50 and collagen plus thrombin were measured at the same agonist conBecause the activities generated in aggregated (stirred), as well as centrations, extracellular Ca 2/ concentration (2.5 mmol/L), platelet nonaggregated (unstirred) platelets were being measured, platelet concentrations, and activation times (10 minutes) as for the proactivation and the prothrombinase assay were performed in the same thrombinase assay, in the presence and absence of stirring, according cuvette to avoid a potentially irreproducible transfer of an aliquot to the procedures described previously. 51 The values of fura-2 fluoof aggregated platelets. Duplicate samples consisting of 280 mL rescence at 340 and 380 nm excitation were corrected for leakage GFP, 7.5 mL 100 mmol/L Ca 2/ , 7.5 or 2.5 mL elution buffer, and 5 of fura-2 using the changes in fluorescence at 340 nm produced by mL of agonist were activated with and without stirring in a Payton sequential additions of 100 mmol/L Mn 2/ and 200 mmol/L DTPADual Channel Aggregometer (Payton Associates, Buffalo, NY). The Ca 2/ to estimate the amount of extracellular fura-2. 52 It should be platelet (plt) concentrations of the GFP were adjusted for each agonoted that, while most conditions in which [Ca 2/ ] i changes were nist, as follows: unstimulated (saline): 1.4 1 10 8 plts/mL; collagen: measured were identical to those in which prothrombinase activity 1.1 1 10 8 plts/mL; thrombin, collagen plus thrombin: 7 1 10 7 plts/ was measured, the stirring speed and efficiency could not be made mL. Unstirred samples were mixed briefly by hand every 2 minutes identical because of the mechanical differences in the instruments during the activation period (see below). Activation was for 10 minused. utes at 37ЊC using 10 mg/mL ''Horm'' collagen, 0.1 U/mL bovine The average calcium concentration for the entire period of platelet thrombin, collagen plus thrombin, or saline. The extent of aggregaactivation, and for intervals during this period, was determined by tion induced by thrombin in stirred normal GFP under these condinumerical analysis of the curves generated by measuring [Ca 2/ ] i at tions was 53% { 3% (n Å 21), confirming the functional capacity 2-second intervals. The method used was one in which the area of these platelets. After 9 minutes of activation, 50 mL each of 27 under a curve is evaluated numerically by means of an integration mmol/L prothrombin, 20 nmol/L factor Va, and 8 mmol/L Ca 2/ /6% formula obtained by interpolating parabolas through a number of albumin was added to each sample with brief mixing. The Ca 2/ / pivotal points of the integrand, using the area under the parabolas albumin was added to preserve the Ca 2/ concentration at 2.5 mmol/ as an approximation to the area under the integrand (Simpson's L and raise the albumin concentration to 1%. In some studies factor rule), and dividing by the time interval over which the area was Va was not added, and was therefore provided entirely by the actidetermined. 53 vated platelets. At 10 minutes, the stir bar was removed from the stirred sample and 50 mL of 20 nmol/L factor Xa was added to each Patients sample. After exactly 1 minute (for thrombin and collagen plus Twenty-eight patients with functional platelet defects were studthrombin) or 3 minutes (for collagen), 50-mL aliquots were transied, including 20 with storage pool deficiency (18 d-SPD, 1 adferred into 450 mL of ice-cold stopping buffer consisting of 10 SPD, 1 a-SPD), 5 with Glanzmann's thrombasthenia, and 3 with an mmol/L TES, 10 mmol/L EDTA, 0.15 mol/L NaCl, and 1% bovine isolated defect in PF3a, including 2 previously unreported patients albumin, pH 7.5. A 3-minute assay time for the collagen-stimulated (MSn and MP). A patient with factor V deficiency, whose platelet samples was used because in preliminary studies, the amounts of defect is assumed to be a specific deficiency of a-granule factor V, thrombin generated during the first minute of the prothrombinase was also studied. assay were found to vary substantially.
The amounts of thrombin generated were determined from the rate of increase of the absorbance at 405 nm in mixtures of 500 mL d-SPD of 0.1 mmol/L Spectrozyme TH in 10 mmol/L TES, 0.15 mol/L Eleven patients (5 males, 6 females) who have the albinism variant NaCl, 1% bovine albumin, pH 7.5, and 25 mL of the 1:10 dilution of d-SPD (Hermansky-Pudlak syndrome, HPS) 45, 46 were studied. All of sample in stopping buffer, and were quantitated by comparison have longstanding bleeding problems of varying severity. Seven of with the rates of increase produced by solutions of known activities these patients have been the subjects of previous reports 45, 54, 55 ; four of purified human a-thrombin or International standard human are new patients, two of whom are sisters with a longstanding history a-thrombin. The platelet concentrations used were those found to of colitis. maintain the amounts of thrombin generated by the activated and Seven non-HPS patients with d-SPD (ES, NS, LG, EP, SKn, unactivated platelets within the linear region of the Spectrozyme SKt, PD) are from a group of previously reported patients. 45, 54 The TH-thrombin standard curves. Prothrombinase activity is expressed deficiencies of dense granule substances in the non-HPS patients are as picomoles of thrombin formed per 10 8 platelets in the 1-minute less pronounced than in those with the HPS variant. The average (thrombin, collagen plus thrombin) or 3-minute (collagen) assay periods. Agonist-specific activity was estimated by subtracting from platelet values ({SE) for these substances, assayed as previously the total activity the value obtained in a parallel saline-treated sample described, 45, 54 seconds. At age 46, she received 10 U of platelets before a total in platelet a-granules (gray platelet syndrome). 57 Both vWF:Ag and abdominal hysterectomy and bilateral salpingo-oophorectomy for fibrinogen are undetectable in her platelets. Platelet ATP, ADP, and intractable pelvic pain and menorrhagia associated with cystic hyperserotonin values are normal. The platelet factor V value was 7 U/ plasia and adenomyosis of the uterus. The surgery was uneventful 10 11 platelets (10% normal). and no postoperative transfusion was required.
Thrombasthenia Patient MSn
Studies were performed on four previously described patients MSn is a 60-year-old woman who has always bruised easily, (MC, CG, LW, LM) whose platelet GPIIb-IIIa is markedly rehas had epistaxis on many occasions, and bled excessively after a duced 41,58 and on one new patient (AE). The binding to their platelets tonsillectomy at age 7, a rhinoplasty at age 19 (requiring rehospitalof 7E3, an MoAb that reacts with both GPIIb-IIIa and a v b 3 , 59 and ization and transfusions), a rectal polypectomy at age 31 (requiring 10E5, which reacts only with GPIIb-IIIa 60 (kindly performed by Dr blood transfusion), and a tooth extraction at age 53. Bleeding after Barry S. Coller, Mt Sinai School of Medicine, New York, NY), was superficial cuts is not prolonged, but rebleeding may occur several (% normal): LW 5.4, 2.6; MC 1.9, 11.4; CG 1.2, 3.4; AE 10.0, 9.0, hours later. Her father and paternal grandmother were also said to and LM 5.8, 10.1. A GPIIb missense mutation (Leu 214 Pro) has have suffered from epistaxis. There is no history of excessive bleedrecently been reported in patient LW. 61 Patient AE is somewhat ing in her mother or her two brothers. She was initially studied in atypical in that his PRP aggregated to a small extent (5% to 13%) our laboratory at age 56, at which time she was taking Premarin with 50 mmol/L ADP on five occasions whereas only a shape change (Wyeth-Ayerst Pharmaceuticals, Philadelphia, PA) and Provera was observed in the other four patients. This small amount of platelet (Pharmacia & Upjohn Co, Kalamazoo, MI), Lopressor (Ciba-Geigy, aggregation was eliminated completely by addition to his PRP of Summit, NJ) for hypertension, and Synthroid for an ''underactive MoAbs against GPIIb-IIIa (7E3 from Dr Coller and LJCP8 from Dr thyroid,'' diagnosed 13 years previously. Except for repeatedly abZaverio M. Ruggeri, La Jolla, CA). The PF3a value on patient AE normal PF3a values, all other tests (those described for patient MP) was 51 seconds whereas it was 58 to 65 seconds in the other patients.
have been normal, including platelet vWF:Ag, b-thromboglobulin, and coagulant factor V values (89%, 103%, and 92% of normal,
Isolated Defects in Platelet Coagulant Activity
respectively). When studied initially, her PF3a value was 69 seconds; Three patients with isolated PCA defects were studied, including repeat studies 3 months later confirmed these findings (PF3a Å the previously reported patient with Scott Syndrome 28 27 Subsequent studies showed that her values of 43 seconds. A breast biopsy at age 58 and a laparoscopic activated platelets exhibited decreased numbers of newly exposed cholecystectomy at age 59, both performed with platelet coverage, membrane binding sites for coagulation factors Va 13, 26 and VIIIa, 62 were uncomplicated. reflecting a diminished surface exposure of phosphatidylserine, 25 and resulting in reduced membrane catalytic activity for both the tenase 25 and prothrombinase complexes. 25, 26 In addition, the capacity of her
Factor V Deficiency platelets to generate microparticles 13 and support fibrin formation on A patient with congenital factor V deficiency was kindly made subendothelium 39 is reduced. The various platelet studies, as well as available by Dr Leonard Stutman (St Vincent's Hospital, New York, those demonstrating decreased procoagulant activity in her RBCs 63 NY). The plasma factor V value was 14% and the platelet coagulant and lymphocytes, 64 that have been performed on this patient have factor V was 8 U/10 11 (12% normal). been summarized recently. 28 
Control Subjects Patient MP
Control subjects were normal hospital personnel. Except where MP is a 46-year-old woman who bled excessively after an appenspecifically indicated, all patients and controls had refrained from dectomy at age 16, a hemorrhoidectomy at age 22, cosmetic eye taking drugs for at least 7 days before study. All studies were persurgery at age 40, and after the birth of one of her two children.
formed under a protocol approved by the Institutional Review Board She does not bruise easily and did not bleed excessively at age 39 of the St Luke's-Roosevelt Institute for Health Sciences. after extraction of a third molar tooth. There is no history of excessive bleeding in her parents, two children, or four siblings. Other medical conditions and diagnoses include fibromyalgia, herniated Statistics intervertebral disc, mitral valve prolapse, and a thyroid nodule, for
Where studies on patients and controls were obtained on more which she has been taking Synthroid (Knoll Pharmaceuticals, Mount than one occasion, the values were averaged. Comparisons of patient Olive, NJ). Normal values were obtained for the bleeding time, and control groups were determined by Student's t-test for either platelet count, activated partial thromboplastin time (APTT), prononpaired or paired samples. thrombin time, and plasma vWF:Ag (75%), factor VIII (132%), and factor V (80% Normal Subjects binase generation. For all agonists tested, the values obtained in unstirred GFP were less than those in stirred GFP ( Fig  Prothrombinase activity was observed in platelets stimu-1A through C). lated with collagen (Table 2) or thrombin alone, and in combination (Table 1, Fig 1) . Collagen plus thrombin-induced Isolated Defects in PCA prothrombinase activity in the absence of added factor Va was 72% of that in the presence of added factor Va, indicatPatients in this group were found initially to have reduced ing that a substantial portion of total prothrombinase activity PF3a, and all had reduced prothrombinase activity with one could be supported by platelet-derived factor Va. Prothromor more agonists. binase activity was also measured in the absence of stirring,
In patient MS with Scott syndrome, the prothrombinase activities, ranging from 32% to 51% of normal, observed to minimize any effects of platelet aggregation on prothrom- Fig 1A through C) . The prothrombinase activities in non-HPS patients ES and NS were also decreased, while less consistent decreases were obtained in the other patients.
a-Granule Defects
The common defect in these patients (a and ad-SPD; factor V deficiency) was a variable reduction in platelet coagulant factor V and an impaired collagen plus thrombin-induced prothrombinase activity in the absence of added factor Va ( Table 1 ). The addition of factor Va completely corrected the latter defect in the factor V-deficient patient, as reported previously, 65 whereas only partial correction was achieved in the patient with a-SPD, and no correction was achieved in the patient with ad-SPD.
Thrombasthenia
The average prothrombinase activities in stirred GFP in the five patients did not differ significantly from those in controls (Table 1 and Fig 1A through C) . However, considerable variation in the individual values obtained with both thrombin and collagen plus thrombin was observed among these patients (data not shown). The values for patient AE were notably increased, and if this somewhat atypical patient (see Materials and Methods) was eliminated from the analy- The most consistent finding in thrombasthenia was an even more striking when expressed as the agonist-specific prothrombinase activity, calculated by subtracting the values obtained for parallel saline-treated samples (constitutive activity) from the total activity (928 { 195 v 183 { 168, P õ with all agonists were similar to the findings in previously .01). reported studies. 13, 25, 26 Figure 1A also shows that, even in thrombasthenic plateIn patient MP, reduced prothrombinase activity was oblets, prothrombinase activities obtained in the presence of tained with some agonists on each of three different occastirring were consistently greater than those obtained in the sions. The most significant reduction (average of 53% norabsence of stirring, indicating that the increased activities mal, ú2 SD) was obtained with collagen plus thrombin in produced by stirring in all subjects (Fig 1) are probably not the absence of added factor Va. The coagulant factor V due solely to the occurrence of platelet aggregation per se. content of her platelets (Table 1) was lower than that in all Platelet coagulant factor V was also strikingly increased but 1 of 15 normal subjects.
in patients with thrombasthenia (Table 1) . This abnormality In patient MSn, a low prothrombinase activity in the abwas not explored further. However, another a-granule consence of factor Va (54% of normal), similar to that found stituent, vWF:Ag, was present in normal amounts (42 { 3 in patient MP, was observed on two of four occasions. The v control values of 43 { 2 U/10 11 ). coagulant factor V content of her platelets was normal.
Dense Granule Defects
Platelet [Ca ] i response seen with all agonists in both stirred and unstirred HPS platelets collagen plus thrombin (Fig 2A) . In contrast, collagen alone induced a delayed and slower increase in [Ca ] i values, calculated as described in Materials and Methods, for the entire period of activation.
observed in stirred, collagen plus thrombin-stimulated GFP ( Fig 1F) and in unstirred, collagen-stimulated GFP (Fig 1D) .
d-SPD. The Ca 2/ responses in SPD-HPS patients were significantly less than those in controls under all conditions
The responses obtained under all other conditions of activation were similar to those in normal subjects ( Fig 1D through  studied (Fig 1D through F) . The basis for this defect is shown in more detail in Fig 3. As seen in Fig 3A, Fig 3A) . to that in normal platelets (953 { 85 nmol/L), this was followed by a rapid decrease in the HPS platelets, in contrast However, the secondary, sustained increase in [Ca 2/ ] i seen in controls was not observed in thrombasthenics, resulting to the secondary and sustained rise observed in normal platelets. A greater than normal decline was also seen in unstirred in an average [Ca 2/ ] i significantly less than that in controls (642 { 45 v 982 { 71 nmol/L, P õ .05). The decline in HPS platelets (Fig 3B) and the initial peak value was also somewhat decreased under these conditions. elevated [Ca 2/ ] i levels was less pronounced in thrombasthenia, however, than in HPS (Fig 3A) . This significantly Limited studies were obtained on four of the non-HPS patients with d-SPD. Although the initial increase in [Ca ] i value (Fig 1F) was associated with a corresponding decrease in prothrombinase activity (Fig was more variable than in the HPS patients, a greater than normal decrease from the initial peak value was also seen 1C), which became statistically significant if the atypical patient AE was eliminated from the analysis. in these patients (data not shown). ] i response in both HPS and normal subjects (Fig 5) . As seen in Fig 5B, ] i in the HPS platelets, and produced a secondary, sustained increase that was almost identical to ]i and prothrombinase responses of that observed in the untreated controls (Fig 5A, 0ADP) . prothrombinase activity (Fig 6D and B) Fig 1D) , and this increased response was DISCUSSION also associated with a corresponding increase in prothrombinase activity (Fig 1A) . The correlation between the [Ca ] i values were also normal in patient MS with Scott syndrome (data not shown), although are essential for normal hemostasis. A second patient with an isolated prothrombinase defect has also been reported the value obtained in stirred platelets stimulated with colla- 
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that a defect in a-granule factor V could be the basis for the impaired prothrombinase activity in patient MP. The importance of this protein in promoting prothrombinase activity is illustrated by the results obtained with and without added factor Va in collagen plus thrombin stimulated platelets from patients with ad-SPD, a-SPD, and factor V deficiency (Table 1) . The most selective and pronounced defect was observed in the patient with factor V deficiency, but this was completely corrected by addition of factor Va. A pronounced defect, which was only partially corrected by added factor Va, was also observed in a-SPD. The failure of factor Va to correct completely the prothrombinase defect in this latter patient was probably due to an almost significant (Ç2 SD) decrease in the prothrombinase activity induced by thrombin alone, which is in contrast to the normal thrombininduced prothrombinase activity reported in a-SPD by Bevers et al. 38 However, the present findings are consistent with our recent observations 57 and those of Srivastava et al 68 that the platelets of some patients with a-SPD have a specific defect in thrombin-induced activation.
A prothrombinase defect has also been described in patients with factor V Quebec, 69 a disorder characterized by deficiencies of platelet factor V 69 and a factor V-binding protein (multimerin) found in a-granules, 70,71 and both quantitative and qualitative abnormalities in other a-granule proteins. 70, 72 In patient MP, both a and ad-SPD are ruled out by the normal values obtained for dense granule substances abnormality, the nature of this defect remains to be determined. We have no explanation at present for the prothrombinase defect in patient MSn, whose platelet coagulant factor recently. 29 In the present study, we have identified two new V is normal. patients (MP and MSn) with relatively severe bleeding disorIn addition to those patients with isolated defects in PCA, ders in whom the only defects were impaired platelet PF3a we also studied platelet prothrombinase activity in patients and prothrombinase activities. Both patients had bled exceswith d-SPD and thrombasthenia. Although the clinical relesively after many surgical procedures, but with platelet covvance of the prothrombinase findings in these latter patients erage patient MP underwent an uncomplicated total abdomiis complicated by their other platelet abnormalities, these nal hysterectomy and bilateral salpingo-oophorectomy, and studies, as well as the parallel studies on intracellular Ca 2/ patient MSn underwent an uncomplicated cholecystectomy. responses, on patients with well-defined platelet defects may The clinical and laboratory findings in these patients thereprovide further information about the mechanisms of profore provide additional evidence that the expression of platethrombinase activation and Ca 2/ responses in normal platelet prothrombinase activity is required for normal hemostalets. sis.
Included in this study were 18 patients with d-SPD, 11 of The basis for the defect in factor Va binding that accounts whom have the typical findings of SPD-HPS. Significantly for the impaired prothrombinase activity in the originally impaired prothrombinase activity in the HPS patients, who described patient with Scott syndrome remains under study, are severely deficient in dense granule substances, was obbut appears to be due to an abnormality in the scramblase served with collagen, thrombin, and collagen plus thrombin mechanism that promotes the translocation of phosphatidylboth in the presence and absence of stirring (Fig 1) . Howserine from the inner to the outer layer of the platelet, as ever, these impairments were less pronounced than those well as the RBC, membrane. 25, 63, 67 The defect in patient MP in Scott syndrome (Table 1) . More variable findings were may differ from that in Scott syndrome. The most significant obtained in the non-HPS d-SPD patients, whose dense granprothrombinase defect in patient MP was observed with colule deficiencies are less severe than those in patients with lagen plus thrombin in the absence of factor Va, and was the HPS. These results thus suggest that dense granules, partially corrected by the addition of factor Va. Her platelet or substances stored in them, may play a role in the full coagulant factor V (64% normal) was also lower than all but 1 of 15 normal subjects. Thus, these findings suggest development of platelet prothrombinase activity. 38 who meacase of collagen stimulation, the absence of cell-cell contact (aggregation) might result in more factor Va binding sites sured prothrombinase activity in a dilute PRP system and reported the pooled values on one HPS and two non-HPS exposed by single thrombasthenic platelets adherent to collagen than by the less activated platelets on the surface of a patients. Of interest, even in their more limited study, the activities in the SPD patients were somewhat lower than normal platelet aggregate, as suggested by others. 40 In contrast, the stronger stimulus provided by collagen plus thromnormal, 38 although the difference did not reach statistical significance. The possible mechanisms that could account bin in stirred platelets may result in aggregation-dependent responses that enhance factor Va binding, and hence profor a prothrombinase defect in d-SPD are discussed below.
The results obtained in five patients with thrombasthenia thrombinase activity, in normal, but not in thrombasthenic platelets. were greatly influenced by the agonist and stirring conditions. In addition, the molecular abnormalities of GPIIb-IIIa
The results of parallel studies on the agonist-induced [Ca 2/ ] i changes in SPD and thrombasthenic platelets may in thrombasthenia may be heterogeneous, 1 and we observed considerable variation among these patients ( Table 2 ). The provide some insights into the mechanisms that could contribute to the abnormal generation of platelet prothrombinase average prothrombinase activity in collagen plus thrombinstimulated, stirred GFP was not statistically different from activity observed in these disorders. In addition, they may provide further insights into the mechanisms controlling actithat in controls, as also reported by Bevers et al 38 in patients with several types of thrombasthenia. However, patient AE, vation-induced intracellular Ca 2/ changes in normal platelets and the relationship of these changes to prothrombinase actiwhose prothrombinase activity was greater than the mean control value, was somewhat atypical in that his platelets vation. The translocation of phosphatidylserine to the outer layer of the plasma membrane, which promotes the generaaggregated to a small extent with 50 mmol/L ADP. If this patient was eliminated from the analysis, the average protion of procoagulant activity, is dependent on both an increase in [Ca ] i values for the period of activation were significantly decreased in the HPS patients in response to collagen, thromthrombinase, and suggest that, under some conditions, GPIIb-IIIa may play a role in supporting prothrombinase bin, and collagen plus thrombin (Fig 1) , and with the latter agonist in particular, this was due primarily to a more rapid activation. Whether this is solely a reflection of the absence of aggregation in thrombasthenic platelets is currently under and extensive decline in elevated [Ca 2/ ] i following the initial increase (Fig 3) . This enhanced decrease was also observed investigation.
In contrast to these findings, prothrombinase activity inin non-HPS patients, in whom the initial [Ca 2/ ] i increases were more variable, perhaps reflecting the heterogeneous duced by collagen alone in unstirred thrombasthenic platelets was consistently greater than that in controls. This increase nature of SPD. 46, 54 For all six conditions of study, there was a significant impairment of both the [Ca 2/ ] i and prothrombiwas even more striking when prothrombinase was calculated as agonist-specific activity (Table 2 ). These observations of nase responses in the HPS patients (Fig 1) . Although these findings are not conclusive of a causal relationship, the conboth increased and decreased prothrombinase activity in thrombasthenia are similar to the results obtained in previous sistent association of impaired prothrombinase activity and decreased average [Ca 2/ ] i levels with all agonists suggests studies, in which increased fibrinopeptide A formation versus that in controls was seen in early samples of blood that this may be the case. It is unlikely that these impaired responses in d-SPD are emerging from bleeding time wounds in thrombasthenics, whereas decreased formation was seen in later samples. 41 caused by the defective platelet aggregation that is characteristically observed in these patients, 45, 46 since both the proAlthough little is known about the comparative ''strengths'' of the collagen and thrombin stimuli that contribute to platethrombinase and [Ca 41 it is highly likely that the proportion and magnitude of these stimuli change considerably over values and prothrombinase activities in HPS patients were considerably less than those in the thrombasthenics (Fig 1) , time during normal hemostasis. Hence, the prothrombinase findings observed in thrombasthenia in this study could be in whom aggregation does not occur, and impaired responses were found only in collagen plus thrombin-stimulated stirred relevant to those observed during hemostasis in these patients.
samples. Both the enhanced decrease in [Ca 2/ ] i and the impaired prothrombinase activity in HPS platelets were corThe reasons for the occurrence of increased and decreased prothrombinase activities, depending on the conditions of rected, however, by the addition of ADP after stimulation, providing further evidence suggesting that the failure to activation, in thrombasthenia remains to be determined. In addition to the possibility of a direct role for GPIIb-IIIa in maintain an adequate [Ca ] i response, but not prothrombinase activin both prothrombinase activation and calcium influx remains unresolved at present. However, our findings of both ity, in normal platelets stimulated with collagen plus thrombin (Fig 5) suggests that, while ADP receptors mediating enhancement and inhibition of these events in thrombasthenic platelets may be related to other conflicting reports Ca 2/ influx may not be fully occupied by the amount of ADP secreted from normal dense granules under these condidescribing the promotion [39] [40] [41] 
